pharma · Renal Transplantation · Rheumatoid Arthritis (RA)
Astellas Pharma
Astellas Pharma Inc
Astellas Pharma patent portfolio — 3 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
- Employees
- 12,378
- Programs
- 0
- Drugs
- 11
- Patents
- 3
Astellas Pharma patents
3 pharmaceutical patents indexed for Astellas Pharma. 0 expire within 24 months.
Astellas Pharma has 3 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
WO 2026078615
ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION
granted -
WO 2026078619
ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION
granted -
US 12097189
Pharmaceutical composition for modified release
granted
Frequently asked questions
How many patents does Astellas Pharma have?
3 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Astellas Pharma patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.